Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160274 · ClinicalTrials.gov registry record
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
A clinical trial of Pheochromocytoma and Paraganglioma, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT03160274: Recruiting study of Pheochromocytoma and Paraganglioma, sponsored by The University of Texas Health Science Center at San Antonio.
NCT03160274 is a study of Pheochromocytoma and Paraganglioma that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 2,000 participants, above the 377-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (431% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03160274, a study of Pheochromocytoma and Paraganglioma, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.
Primary Outcome
Genetic screen detects a mutation that is likely responsible for tumor development
Conditions Studied
Interventions
- GENETIC Genetic screening
Study Locations (1)
Texas
- University of Texas Health Science Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-10-19 |
| Est. Completion | 2030-12-31 |
What NCT03160274 shows while recruiting
NCT03160274 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 377-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (431% higher).
The record links to 8 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 1 intervention - of which Genetic screening is the first listed.
NCT03160274 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03160274 about?
NCT03160274 is a clinical study titled "Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions". Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The a...
What is the current status of trial NCT03160274?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2005-10-19. Estimated completion is 2030-12-31.
What conditions does trial NCT03160274 study?
This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma, Kidney Neoplasms, Thyroid Neoplasms, Other Cancer.
What interventions are being tested in trial NCT03160274?
The interventions under investigation include: Genetic screening (GENETIC).
Who is sponsoring clinical trial NCT03160274?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03160274 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pheochromocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03160274's enrollment target sits among peer trials
2,000 2nd of 14 the highest of 14 other Pheochromocytoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pheochromocytoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
RECRUITING · Phase 1
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Diagnosis of Pheochromocytoma
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
RECRUITING · Phase 1
-
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI